Sökning: id:"swepub:oai:DiVA.org:uu-412690" >
Apixaban Versus War...
-
Stanifer, John W.Munson Healthcare, Munson Nephrol, Traverse City, MI USA.
(författare)
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease
- Artikel/kapitelEngelska2020
Förlag, utgivningsår, omfång ...
-
LIPPINCOTT WILLIAMS & WILKINS,2020
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-412690
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-412690URI
-
https://doi.org/10.1161/CIRCULATIONAHA.119.044059DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: Compared with the general population, patients with advanced chronic kidney disease have a >10-fold higher burden of atrial fibrillation. Limited data are available guiding the use of nonvitamin K antagonist oral anticoagulants in this population.Methods: We compared the safety of apixaban with warfarin in 269 patients with atrial fibrillation and advanced chronic kidney disease (defined as creatinine clearance [CrCl] 25 to 30 mL/min) enrolled in the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). Cox proportional models were used to estimate hazard ratios for major bleeding and major or clinically relevant nonmajor bleeding. We characterized the pharmacokinetic profile of apixaban by assessing differences in exposure using nonlinear mixed effects models.Results: Among patients with CrCl 25 to 30 mL/min, apixaban caused less major bleeding (hazard ratio, 0.34 [95% CI, 0.14-0.80]) and major or clinically relevant nonmajor bleeding (hazard ratio, 0.35 [95% CI, 0.17-0.72]) compared with warfarin. Patients with CrCl 25 to 30 mL/min randomized to apixaban demonstrated a trend toward lower rates of major bleeding when compared with those with CrCl >30 mL/min (P interaction=0.08) and major or clinically relevant nonmajor bleeding (P interaction=0.05). Median daily steady-state areas under the curve for apixaban 5 mg twice daily were 5512 ng/(mL center dot h) and 3406 ng/(mL center dot h) for patients with CrCl 25 to 30 mL/min or >30 mL/min, respectively. For apixaban 2.5 mg twice daily, the median exposure was 2780 ng/(mL center dot h) for patients with CrCl 25 to 30 mL/min. The area under the curve values for patients with CrCl 25 to 30 mL/min fell within the ranges demonstrated for patients with CrCl >30 mL/min.Conclusions: Among patients with atrial fibrillation and CrCl 25 to 30 mL/min, apixaban caused less bleeding than warfarin, with even greater reductions in bleeding than in patients with CrCl >30 mL/min. We observed substantial overlap in the range of exposure to apixaban 5 mg twice daily for patients with or without advanced chronic kidney disease, supporting conventional dosing in patients with CrCl 25 to 30 mL/min. Randomized, controlled studies evaluating the safety and efficacy of apixaban are urgently needed in patients with advanced chronic kidney disease, including those receiving dialysis.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Pokorney, Sean D.Duke Univ, Div Cardiol, Dept Med, Duke Hlth,Sch Med, Durham, NC USA.;Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
(författare)
-
Chertow, Glenn M.Stanford Univ, Sch Med, Div Nephrol, Stanford, CA 94305 USA.
(författare)
-
Hohnloser, Stefan H.Goethe Univ Frankfurt, Frankfurt, Germany.
(författare)
-
Wojdyla, Daniel M.Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
(författare)
-
Garonzik, SamiraBristol Myers Squibb Co, Clin Pharmacol & Pharmacometr, Princeton, NJ USA.
(författare)
-
Byon, WonkyungPfizer Inc, Global Prod Dev Clin Pharmacol, Groton, CT 06340 USA.
(författare)
-
Hijazi, ZiadUppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)ziahi940
(författare)
-
Lopes, Renato D.Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
(författare)
-
Alexander, John H.Duke Univ, Div Cardiol, Dept Med, Duke Hlth,Sch Med, Durham, NC USA.;Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
(författare)
-
Wallentin, Lars,1943-Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)larswall
(författare)
-
Granger, Christopher B.Duke Univ, Div Cardiol, Dept Med, Duke Hlth,Sch Med, Durham, NC USA.;Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
(författare)
-
Munson Healthcare, Munson Nephrol, Traverse City, MI USA.Duke Univ, Div Cardiol, Dept Med, Duke Hlth,Sch Med, Durham, NC USA.;Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Circulation: LIPPINCOTT WILLIAMS & WILKINS141:17, s. 1384-13920009-73221524-4539
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Stanifer, John W ...
-
Pokorney, Sean D ...
-
Chertow, Glenn M ...
-
Hohnloser, Stefa ...
-
Wojdyla, Daniel ...
-
Garonzik, Samira
-
visa fler...
-
Byon, Wonkyung
-
Hijazi, Ziad
-
Lopes, Renato D.
-
Alexander, John ...
-
Wallentin, Lars, ...
-
Granger, Christo ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Circulation
- Av lärosätet
-
Uppsala universitet